Breast Biopsy Market Research Synopsis 2021 – with a CAGR of 4.80%

The Global Breast Biopsy Market size is estimated to be USD 1.14 billion in 2019 and is predicted to reach USD 1.91 billion by 2030 with a CAGR of 4.80% from 2020-2030.

Breast biopsy is a procedure conducted to remove a small sample of breast tissue or fluid for laboratory testing. This diagnostic procedure is performed to evaluate the breast cells for the presence of breast cancer. Breast biopsy can be performed surgically or with the help of minimally invasive techniques by a radiologists.

Several types of breast biopsy procedures are performed to obtain a tissue sample. Some of the breast biopsy procedures include fine-needle aspiration biopsy, core needle biopsy, stereotactic biopsy, and so on. Physicians generally recommend a particular procedure based on the size, location and other characteristics of the breast abnormality. Additionally, breast imaging plays a significant role in cancer diagnosis to confirm visual findings. For the procedure to be successful, there has to be strong correlation mammographic data and the biopsy system’s findings. Thus, image guided breast biopsies are currently considered to be a first line approach for tissue diagnosis and helps in reducing the morbidity rate. Advancements in imaging technology thus, provides significant growth opportunities for the players in the breast biopsy market.

Access Full Description of this report at:-

https://www.nextmsc.com/report/breast-biopsy-market

Top Companies: Biomed Diagnostics, F. Hoffmann-La Roche Ltd., Hologic Inc., C.R Bard, Inc., Devicor Medicals Products, Inc., Ethicon, Cook Medical Incorporated, Scion Medical Technologies, Argon Medical Devices and Becton, Dickinson and Company and others.

Market Dynamics and Trends:

Globally, the number of breast cancer cases are rapidly increasing. According to the World Cancer Research Fund, globally there were over 2 million new cases of breast cancer in 2018. Changing lifestyle habits and genetic abnormalities leads to development of breast cancer in most of the women worldwide. Due to this increasing incidence rate, governments across countries are taking initiatives to create awareness about breast cancer and are also funding research projects to develop appropriate diagnostic and therapeutic alternatives. Number of breast screening programs are being held and renewed reimbursement guidelines are being announced for breast screening/breast biopsy procedures. These factors are likely to fuel to the growth of breast biopsy market globally. However, risks related to invasive biopsy procedures and substandard healthcare facilities especially in developing regions are likely to restrain the growth of this market.

With a primary focus of business development, players such as Hologic, Roche, Cook Medical and Ethicon mainly emphasize on product development and product launches. In August 2017, Hologic announced commercial launch of Brevera breast biopsy system with CorLumina imaging technology, in the US. Also, in January 2016 Genomic Health announced launch of liquid biopsy test, Oncotype SEQ. In addition to this, strategic collaborations for research and development and geographic expansion also create a competitive environment in the global breast biopsy market.

Request sample copy of this report at:-

https://www.nextmsc.com/Breast-Biopsy-Market/request-sample

Market Segmentations and Scope of the Study:

The breast biopsy market share is analysed on the basis of type, product, end user and geography. The type segment covers the market for needle breast biopsy, surgical breast biopsy. By product the market is divided into biopsy needles, biopsy tables, localization wires, guidance systems, and others. On the basis of end user the market is segmented into hospitals, cancer research organizations, diagnostic laboratories, and other end users. The geographical segmentation covers North America, Europe, Asia Pacific, and Rest of the World.

Contact:
Phone Number: +1-217-650-7991
E-mail: info@nextmsc.com

About Next Move Strategy Consulting:

Next Move Strategy Consulting is an independent and trusted third-platform market intelligence provider, committed to deliver high quality, market research reports that help multinational companies to triumph over their competitions and increase industry footprint by capturing greater market share. Our research model is a unique collaboration of primary research, secondary research, data mining and data analytics.

We have been servicing over 1000 customers globally that includes 90% of the Fortune 500 companies over a decade. Our analysts are constantly tracking various high growth markets and identifying hidden opportunities in each sector or the industry. We provide one of the industry’s best quality syndicate as well as custom research reports across 10 different industry verticals. We are committed to deliver high quality research solutions in accordance to your business needs. Our industry standard delivery solution that ranges from the pre consultation to after-sales services, provide an excellent client experience and ensure right strategic decision making for businesses.

For more insights, please visit, https://www.nextmsc.com

This release was published on openPR.